International Stem Cell Corp. Company Profile (OTCMKTS:ISCO)

About International Stem Cell Corp. (OTCMKTS:ISCO)

International Stem Cell Corp. logoInternational Stem Cell Corporation (ISCO) is a biotechnology company. The Company is focused on therapeutic and biomedical product development. The Company's segments include Therapeutic Market, Cosmetic Market and Biomedical Market. The Company's subsidiaries include International Stem Cell Corporation, a research and development company, for the Therapeutic Market for clinical applications of human parthenogenetic stem cells (hpSCs) for the treatment of various diseases, such as Parkinson's disease, liver diseases and corneal blindness; Cyto Therapeutics, PTY LTD, a research and development company, for the Therapeutic Market; Lifeline Skin Care, Inc. for the Cosmetic Market, which develops, manufactures and markets a category of cosmetic skin care products based on biotechnology with human stem cells, and Lifeline Cell Technology, LLC for the Biomedical Market, which develops, manufactures and commercializes primary human cell research products.

Industry, Sector and Symbol: Capitalization:
  • Market Cap: $5.81 million
  • Outstanding Shares: 4,004,000
Average Prices:
  • 50 Day Moving Avg: $1.21
  • 200 Day Moving Avg: $1.37
  • 52 Week Range: $0.65 - $2.50
P/E:
  • Trailing P/E Ratio: 0.50
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $7.55 million
  • Price / Sales: 0.79
  • Book Value: $0.16 per share
  • Price / Book: 9.31
Profitability:
  • EBIDTA: ($4,000,000.00)
  • Net Margins: 137.81%
  • Return on Equity: 1,193.12%
  • Return on Assets: 137.47%
Debt:
  • Current Ratio: 0.45%
  • Quick Ratio: 0.26%
Misc:
  • Average Volume: 3,352 shs.
  • Beta: 0.17
 
Frequently Asked Questions for International Stem Cell Corp. (OTCMKTS:ISCO)

What is International Stem Cell Corp.'s stock symbol?

International Stem Cell Corp. trades on the OTCMKTS under the ticker symbol "ISCO."

How were International Stem Cell Corp.'s earnings last quarter?

International Stem Cell Corp. (OTCMKTS:ISCO) issued its earnings results on Wednesday, May, 17th. The company reported ($0.78) earnings per share (EPS) for the quarter. The business had revenue of $2.01 million for the quarter. International Stem Cell Corp. had a return on equity of 1,193.12% and a net margin of 137.81%. View International Stem Cell Corp.'s Earnings History.

Who are some of International Stem Cell Corp.'s key competitors?

Who are International Stem Cell Corp.'s key executives?

International Stem Cell Corp.'s management team includes the folowing people:

  • Andrey Semechkin Ph.D., Co-Chairman of the Board, Chief Executive Officer
  • Donald Arthur Wright, Independent Co-Chairman of the Board
  • Mahnaz Ebrahimi, Chief Financial Officer, Secretary
  • Russell Kern Ph.D., Executive Vice President, Chief Scientific Officer
  • Charles J. Casamento, Executive Director and Principal, The Sage Group
  • Paul V. Maier, Independent Director

How do I buy International Stem Cell Corp. stock?

Shares of International Stem Cell Corp. can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is International Stem Cell Corp.'s stock price today?

One share of International Stem Cell Corp. stock can currently be purchased for approximately $1.49.


MarketBeat Community Rating for International Stem Cell Corp. (OTCMKTS ISCO)
Community Ranking:  2.3 out of 5 ( )
Outperform Votes:  5 (Vote Outperform)
Underperform Votes:  6 (Vote Underperform)
Total Votes:  11
MarketBeat's community ratings are surveys of what our community members think about International Stem Cell Corp. and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for International Stem Cell Corp. (OTCMKTS:ISCO) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for International Stem Cell Corp. (OTCMKTS:ISCO)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for International Stem Cell Corp. (OTCMKTS:ISCO)
Earnings by Quarter for International Stem Cell Corp. (OTCMKTS:ISCO)
Earnings History by Quarter for International Stem Cell Corp. (OTCMKTS ISCO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/17/2017Q1 2017($0.78)$2.01 millionViewN/AView Earnings Details
11/14/2016Q3 2016($0.30)$1.94 millionViewN/AView Earnings Details
11/13/2014Q3 2014($0.01)($0.01)$1.90 million$1.96 millionViewN/AView Earnings Details
8/12/2014Q2 2014($0.01)($0.01)$1.85 million$1.59 millionViewN/AView Earnings Details
11/13/2013($0.03)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for International Stem Cell Corp. (OTCMKTS:ISCO)

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for International Stem Cell Corp. (OTCMKTS:ISCO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for International Stem Cell Corp. (OTCMKTS:ISCO)
Insider Ownership Percentage: 82.32%
Insider Trades by Quarter for International Stem Cell Corp. (OTCMKTS:ISCO)
Insider Trades by Quarter for International Stem Cell Corp. (OTCMKTS:ISCO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/22/2017Andrey SemechkinCEOBuy3,200$1.64$5,248.00View SEC Filing  
3/22/2017Andrey SemechkinCEOBuy10,000$1.67$16,700.00View SEC Filing  
3/14/2017Andrey SemechkinCEOBuy8,100$1.41$11,421.00View SEC Filing  
12/8/2016Andrey SemechkinCEOBuy285,714$1.75$499,999.50View SEC Filing  
9/14/2016Andrey SemechkinCEOBuy200,000$1.75$350,000.00View SEC Filing  
8/22/2016Andrey SemechkinCEOBuy154,285$1.75$269,998.75View SEC Filing  
6/29/2016Andrey SemechkinCEOBuy215,000$1.75$376,250.00View SEC Filing  
8/6/2014Ruslan SemechkinMajor ShareholderBuy1,000,000$0.10$100,000.00View SEC Filing  
1/22/2013Andrey SemechkinCEOBuy10,000,000$0.20$2,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for International Stem Cell Corp. (OTCMKTS:ISCO)
Latest Headlines for International Stem Cell Corp. (OTCMKTS:ISCO)
Source:
DateHeadline
finance.yahoo.com logoInternational Stem Cell Corp. :ISCO-US: Earnings Analysis: Q1, 2017 By the Numbers : June 13, 2017
finance.yahoo.com - June 13 at 10:50 AM
americanbankingnews.com logoInternational Stem Cell Corp (ISCO) Issues Earnings Results
www.americanbankingnews.com - May 18 at 10:44 AM
finance.yahoo.com logoInternational Stem Cell Corporation Announces Operating Results for the Quarter ended March 31, 2017
finance.yahoo.com - May 17 at 9:54 AM
reuters.com logoBRIEF-International Stem Cell receives approval to start second patient cohort in clinical trial for Parkinson’s disease
www.reuters.com - May 11 at 11:35 PM
marketwatch.com logoStem Cells Market 2022 Global Trends and Analysis Research Report Now Available at ReportsnReports.com
www.marketwatch.com - May 11 at 11:35 PM
finance.yahoo.com logoInternational Stem Cell Corporation Receives Approval to Start Second Patient Cohort in Clinical Trial for Parkinson’s Disease
finance.yahoo.com - May 9 at 12:19 PM
finance.yahoo.com logoInternational Stem Cell Corporation to Present Results of Neural Stem Cell Transplantation for Parkinson's Disease at the ASGCT 2017 Annual Meeting
finance.yahoo.com - May 4 at 11:31 AM
seekingalpha.com logo3 Things In Biotech You Should Learn Today: April 27, 2017
seekingalpha.com - April 28 at 6:57 PM
finance.yahoo.com logoInternational Stem Cell Corporation Completes First Cohort In Parkinson's Disease Clinical Trial
finance.yahoo.com - April 25 at 10:39 AM
finance.yahoo.com logoInternational Stem Cell Corporation Announces 2016 Fourth Quarter and Year-End Results
finance.yahoo.com - April 7 at 10:32 AM
finance.yahoo.com logoInternational Stem Cell Corp. :ISCO-US: Earnings Analysis: Q4, 2016 By the Numbers : April 5, 2017
finance.yahoo.com - April 7 at 10:32 AM
biz.yahoo.com logoINTERNATIONAL STEM CELL CORP Files SEC form 10-K, Annual Report
biz.yahoo.com - March 31 at 6:00 PM
americanbankingnews.com logoInternational Stem Cell Corp (ISCO) CEO Andrey Semechkin Purchases 10,000 Shares
www.americanbankingnews.com - March 22 at 8:34 PM
americanbankingnews.com logoInsider Buying: International Stem Cell Corp (ISCO) CEO Purchases 8,100 Shares of Stock
www.americanbankingnews.com - March 15 at 12:24 AM
biz.yahoo.com logoINTERNATIONAL STEM CELL CORP Files SEC form 8-K, Entry into a Material Definitive Agreement
biz.yahoo.com - March 1 at 11:39 AM
finance.yahoo.com logoInternational Stem Cell Corporation Announces Third Patient with Parkinson's Disease in Phase I Clinical Trial
finance.yahoo.com - February 28 at 9:23 AM
biz.yahoo.com logoINTERNATIONAL STEM CELL CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and
biz.yahoo.com - January 18 at 6:31 PM
finance.yahoo.com logoInternational Stem Cell Corporation Announces Second Patient with Parkinson’s Disease Treated in Phase I Clinical Trial
finance.yahoo.com - December 7 at 6:07 PM
finance.yahoo.com logoInternational Stem Cell Corporation Announces Second Patient with Parkinson's Disease Treated in Phase I Clinical Trial
finance.yahoo.com - December 7 at 6:07 PM
reuters.com logoBRIEF-International Stem Cell Q3 revenue falls 9 pct to $1.94 mln
www.reuters.com - November 16 at 5:57 PM
finance.yahoo.com logoInternational Stem Cell Corporation Announces Operating Results for the Three and Nine-months ended September …
finance.yahoo.com - November 16 at 9:18 AM
finance.yahoo.com logoInternational Stem Cell Corporation to Present Results of Neural Stem Cell Transplantation for Parkinson’s Disease at the Neuroscience 2016 Conference
finance.yahoo.com - November 10 at 5:12 PM
finance.yahoo.com logoInternational Stem Cell Corporation Publishes Results of Safety Studies Conducted in Support of the First Human Pluripotent Stem Cell Based Therapy for Parkinson’s Disease
finance.yahoo.com - October 5 at 10:54 AM
finance.yahoo.com logoInternational Stem Cell Corp (ISCO) CEO Andrey Semechkin Bought $350,000 of Shares
finance.yahoo.com - September 15 at 6:06 PM
prnewswire.com logoEdison Issues Update on International Stem Cell (ISCO)
www.prnewswire.com - August 2 at 10:30 AM
globenewswire.com logoISC-hpNSC transplantation is being evaluated for the treatment of Parkinson’s Disease
globenewswire.com - July 28 at 8:45 AM
finance.yahoo.com logoInternational Stem Cell Corporation Announces Successful Cell Transplantation for the First Patient in Phase 1 Clinical Trial of ISC-hpNSC
finance.yahoo.com - July 28 at 8:30 AM
huffingtonpost.com logoStem Cell Partnership: Patient Advocates And Scientists At The International Society For Stem Cell Research Convention
www.huffingtonpost.com - July 10 at 5:17 PM
biz.yahoo.com logoINTERNATIONAL STEM CELL CORP Files SEC form 8-K, Unregistered Sale of Equity Securities
biz.yahoo.com - July 6 at 2:08 PM
reuters.com logoInternational Stem Cell Corp (ISCO.PK)
www.reuters.com - June 17 at 5:36 PM

Social

Chart

International Stem Cell Corp. (ISCO) Chart for Friday, July, 28, 2017

This page was last updated on 7/28/2017 by MarketBeat.com Staff